255 related articles for article (PubMed ID: 37650539)
1. Physiological determinants and plausible '6R' roadmap for clinical success of nanomedicines.
Shahiwala A
Nanomedicine (Lond); 2023 Aug; 18(18):1207-1222. PubMed ID: 37650539
[TBL] [Abstract][Full Text] [Related]
2. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
3. Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.
He H; Liu L; Morin EE; Liu M; Schwendeman A
Acc Chem Res; 2019 Sep; 52(9):2445-2461. PubMed ID: 31424909
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticles with transformable physicochemical properties for overcoming biological barriers.
Lu Q; Yu H; Zhao T; Zhu G; Li X
Nanoscale; 2023 Aug; 15(32):13202-13223. PubMed ID: 37526946
[TBL] [Abstract][Full Text] [Related]
5. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
Patel P; Shah J
Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
[TBL] [Abstract][Full Text] [Related]
6. Unlocking the Mitochondria for Nanomedicine-based Treatments: Overcoming Biological Barriers, Improving Designs, and Selecting Verification Techniques.
Pegoraro C; Domingo-Ortí I; Conejos-Sánchez I; Vicent MJ
Adv Drug Deliv Rev; 2024 Apr; 207():115195. PubMed ID: 38325562
[TBL] [Abstract][Full Text] [Related]
7. Obstacles and opportunities in a forward vision for cancer nanomedicine.
de Lázaro I; Mooney DJ
Nat Mater; 2021 Nov; 20(11):1469-1479. PubMed ID: 34226688
[TBL] [Abstract][Full Text] [Related]
8. Evaluating Nanomedicines: Obstacles and Advancements.
Swierczewska M; Crist RM; McNeil SE
Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
[TBL] [Abstract][Full Text] [Related]
9. Clinical translation of nanomedicines: Challenges, opportunities, and keys.
Younis MA; Tawfeek HM; Abdellatif AAH; Abdel-Aleem JA; Harashima H
Adv Drug Deliv Rev; 2022 Feb; 181():114083. PubMed ID: 34929251
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary delivery nanomedicines towards circumventing physiological barriers: Strategies and characterization approaches.
Wang W; Huang Z; Huang Y; Zhang X; Huang J; Cui Y; Yue X; Ma C; Fu F; Wang W; Wu C; Pan X
Adv Drug Deliv Rev; 2022 Jun; 185():114309. PubMed ID: 35469997
[TBL] [Abstract][Full Text] [Related]
11. Nanomedicine Tumor Targeting.
Lammers T
Adv Mater; 2024 Jun; 36(26):e2312169. PubMed ID: 38361435
[TBL] [Abstract][Full Text] [Related]
12. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
[TBL] [Abstract][Full Text] [Related]
13. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.
Kompella UB; Amrite AC; Pacha Ravi R; Durazo SA
Prog Retin Eye Res; 2013 Sep; 36():172-98. PubMed ID: 23603534
[TBL] [Abstract][Full Text] [Related]
14. Effect of biophysical properties of tumor extracellular matrix on intratumoral fate of nanoparticles: Implications on the design of nanomedicine.
Tian Y; Cheng T; Sun F; Zhou Y; Yuan C; Guo Z; Wang Z
Adv Colloid Interface Sci; 2024 Apr; 326():103124. PubMed ID: 38461766
[TBL] [Abstract][Full Text] [Related]
15. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective.
Hare JI; Lammers T; Ashford MB; Puri S; Storm G; Barry ST
Adv Drug Deliv Rev; 2017 Jan; 108():25-38. PubMed ID: 27137110
[TBL] [Abstract][Full Text] [Related]
16. Smart cancer nanomedicine.
van der Meel R; Sulheim E; Shi Y; Kiessling F; Mulder WJM; Lammers T
Nat Nanotechnol; 2019 Nov; 14(11):1007-1017. PubMed ID: 31695150
[TBL] [Abstract][Full Text] [Related]
17. Zebrafish as a preclinical in vivo screening model for nanomedicines.
Sieber S; Grossen P; Bussmann J; Campbell F; Kros A; Witzigmann D; Huwyler J
Adv Drug Deliv Rev; 2019; 151-152():152-168. PubMed ID: 30615917
[TBL] [Abstract][Full Text] [Related]
18. Smart Nanosystems for Overcoming Multiple Biological Barriers in Cancer Nanomedicines Transport: Design Principles, Progress, and Challenges.
Lin G; Zhou J; Cheng H; Liu G
Small; 2023 Jul; 19(28):e2207973. PubMed ID: 36971279
[TBL] [Abstract][Full Text] [Related]
19. Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.
Balasubramanian V; Liu Z; Hirvonen J; Santos HA
Adv Healthc Mater; 2018 Jan; 7(1):. PubMed ID: 28570787
[TBL] [Abstract][Full Text] [Related]
20. Physiological principles underlying the kidney targeting of renal nanomedicines.
Huang Y; Ning X; Ahrari S; Cai Q; Rajora N; Saxena R; Yu M; Zheng J
Nat Rev Nephrol; 2024 Jun; 20(6):354-370. PubMed ID: 38409369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
